地西他滨治疗血液系统恶性肿瘤的研究进展

Treatment evolution in hematopoitic malignancies with an hypomethylating agent decitabine

随着表观遗传学研究的不断深入,研究人员发现DNA的异常甲基化在恶性血液肿瘤的发生和发展中有着重要作用。地西他滨(DAC)是一种DNA甲基转移酶(DNMT)抑制剂,作为一种研究较为成熟的去甲基化药物,由于其较好的临床疗效和独特的作用机制,临床上被广泛用于治疗各种类型的骨髓增生异常综合征(MDS)、急性髓细胞白血病(AML)等其他血液恶性疾病。该文就地西他滨的作用机制、药代动力学以及在各种血液系统恶性疾病中的研究进展作一综述。

With the deepeningstudy of epigenetic,the researchers find that DNA methylation play an important role during the transfor-mation of hematopoitic malignancies. The decitabine as an inhibitor of DNA methyltransferase is a well studied hypomethylation drug. Itis wildly used to treat various myelodysplastic syndrome（MDS）,acute myelogenous leukemia（AML）and other hematopoitic malignan-cies,due to its unique mechanism and better clinical effectiveness. In this paper,itsmechanism,pharmacology,research progress in he-matopoitic malignanciesare reviewed.